JP2012533065A5 - - Google Patents

Download PDF

Info

Publication number
JP2012533065A5
JP2012533065A5 JP2012519637A JP2012519637A JP2012533065A5 JP 2012533065 A5 JP2012533065 A5 JP 2012533065A5 JP 2012519637 A JP2012519637 A JP 2012519637A JP 2012519637 A JP2012519637 A JP 2012519637A JP 2012533065 A5 JP2012533065 A5 JP 2012533065A5
Authority
JP
Japan
Prior art keywords
saa
diabetes
ratio
subject
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012519637A
Other languages
English (en)
Japanese (ja)
Other versions
JP5748751B2 (ja
JP2012533065A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/040997 external-priority patent/WO2011005717A1/en
Publication of JP2012533065A publication Critical patent/JP2012533065A/ja
Publication of JP2012533065A5 publication Critical patent/JP2012533065A5/ja
Application granted granted Critical
Publication of JP5748751B2 publication Critical patent/JP5748751B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012519637A 2009-07-07 2010-07-02 糖尿病前症及び２型糖尿病における血清アミロイドの表現型比率 Active JP5748751B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22349809P 2009-07-07 2009-07-07
US61/223,498 2009-07-07
PCT/US2010/040997 WO2011005717A1 (en) 2009-07-07 2010-07-02 Phenotypic ratio of serum amyloid in pre- and type 2 diabetes

Publications (3)

Publication Number Publication Date
JP2012533065A JP2012533065A (ja) 2012-12-20
JP2012533065A5 true JP2012533065A5 (enExample) 2013-05-30
JP5748751B2 JP5748751B2 (ja) 2015-07-15

Family

ID=43427764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519637A Active JP5748751B2 (ja) 2009-07-07 2010-07-02 糖尿病前症及び２型糖尿病における血清アミロイドの表現型比率

Country Status (5)

Country Link
US (1) US20110008799A1 (enExample)
EP (1) EP2451465B1 (enExample)
JP (1) JP5748751B2 (enExample)
CN (1) CN102481320A (enExample)
WO (1) WO2011005717A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160112810A (ko) * 2015-03-20 2016-09-28 삼성전자주식회사 이미지 처리 방법 및 그 전자 장치
CN113080114A (zh) * 2021-04-12 2021-07-09 浙江大学 一种提高鱼类子代成活率的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164818A1 (en) * 1995-05-23 2002-11-07 Gruber Karl F. Mass spectrometric immunoassay analysis of specific proteins and variants present in various biological fluids
JP2005503537A (ja) * 2001-01-17 2005-02-03 エー． タブス，ケモンズ 生体分子分析用ハイ・スループット統合システム
AUPR589801A0 (en) * 2001-06-22 2001-07-19 Autogen Research Pty Ltd Modulation of physiological processes and agents useful for same
US20070087448A1 (en) * 2004-02-16 2007-04-19 Nelsestuen Gary L Biological profiles and methods of use
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
JP2008228646A (ja) * 2007-03-20 2008-10-02 Hokkaido Univ ２型糖尿病診断剤
CA2692970A1 (en) * 2007-07-03 2009-01-08 Northeastern University Biomarkers for diabetes, obesity, and/or hypertension

Similar Documents

Publication Publication Date Title
Choudhary et al. Frequency of biochemical hypoglycaemia in adults with type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring
Adam et al. Integration of microfluidic channel on electrochemical-based nanobiosensors for monoplex and multiplex analyses: an overview
Blomqvist et al. Salivary cortisol levels and dental anxiety in children with attention deficit hyperactivity disorder
Makris et al. Is there a relationship between mean blood glucose and glycated hemoglobin?
WO2010053587A3 (en) Methods of monitoring conditions by sequence analysis
Mayega et al. Comparison of fasting plasma glucose and haemoglobin A1c point-of-care tests in screening for diabetes and abnormal glucose regulation in a rural low income setting
Sung et al. Progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes
EP2369346A3 (en) Means and method for diagnosing diabetes
JP2011516046A5 (enExample)
WO2006026020A3 (en) Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
JP2012068263A5 (enExample)
EP3039422A1 (en) Device and methods of using device for detection of hyperammonemia
WO2006073682A3 (en) Diagnostic test
Bresciani et al. Accuracy of capillary blood 3-β-hydroxybutyrate determination for the detection and treatment of canine diabetic ketoacidosis
Sylvestre et al. Untargeted metabolomic analysis of plasma from relapsing-remitting multiple sclerosis patients reveals changes in metabolites associated with structural changes in brain
JP2012533066A5 (enExample)
Zhang et al. A strategy for the development of biomarker tests for PTSD
NZ592819A (en) Thyroid analyte detection and measurement
JP2012533065A5 (enExample)
Ma et al. Evaluation of sweat-based biomarkers using wearable biosensors for monitoring stress and fatigue: a systematic review
Paroni et al. Lactulose and mannitol intestinal permeability detected by capillary electrophoresis
EP1376133A4 (en) SCREENING PROCEDURE FOR THE PRÄDIABETIS CONDITION AND SCREENING REAGENT
Chubb et al. The relationship between self-monitoring of blood glucose results and glycated haemoglobin in type 2 diabetes: the fremantle diabetes study
CN111455076B (zh) 用于儿童孤独症评估的口腔菌群微生物
Arora et al. Point-of-care beta-hydroxybutyrate testing for assessing diabetic ketoacidosis severity prior to treatment in the emergency department